Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases

At the ESMO Congress 2026, the phase 3 randomized, double-blind, placebo-controlled EMT2 trial showed that 4 g daily EPA was associated with longer overall survival in patients undergoing resection of colorectal cancer liver metastases, with estimated 5-year overall survival of 62.0% versus 45.1% for placebo.